Abeona therapeutics announces positive topline results with both co-primary endpoints met in pivotal phase 3 viital™ study of eb-101

Co-primary endpoint measuring > 50% wound healing, other endpoints measuring > 75% and complete wound healing at six months all met

ABEO Ratings Summary

ABEO Quant Ranking